Science
About INTASYL™
How INTASYL™ Works
Pipeline
Program
Discovery
Preclinical Proof
of Concept
IND Enabling
Studies
IND Clearance
Clinical Phase
PH-762
(PD-1 protein silencer)
Intratumoral Administration
Target Indications: Stages I, II, and IV cSCC, Stage IV Melanoma, and Stage IV Merkel cell carcinoma
Read More
Target(s) & Indications: Stages I, II, and IV cSCC, Stage IV Melanoma, and Stage IV Merkel cell carcinoma
PH-762
(PD-1 protein silencer)+Adoptive Cell Therapy (Double Positive (DP) CD8 tumor infiltrating lymphocytes (Tils))
Target Indications: Stage IV Melanoma, solid tumor malignancies
Read More
Target(s) & Indication:Stage IV Melanoma, solid tumor malignancies
PH-894
(BRD4 protein silencer
Target Indications: Stage IV Melanoma, HNSCC, HCC, HPV-related c SCC
Intratumoral Administration
Read More
PH-894 precisely silences only the BRD4 protein, a specific member of the BET protein family. BRD4 is a critical regulator of gene expression involved in cancer progression and metastasis and offers the potential to reduce immune-related adverse events.
Target(s) & Indication: Stage IV Melanoma, HNSCC, HCC, HPV-related c SCC
Key Clinical Initiatives & Programs
PH-762 (PD-1 Protein Silencer)
- The on-going Phase 1b trial is a neoadjuvant dose escalation study of intratumoral administration of PH-762 in adult patients with cutaneous squamous cell carcinoma, Stage IV melanoma, or Stage IV Merkel cell carcinoma. The trial is designed to evaluate the safety, assess tumor size, pharmacokinetics and biomarker analyses, and to determine the dose or dose range for continued study of PH-762.
- Learn more in Scientific Resources
- Learn more about the clinical trial.(NCT # 06014086)
PH-894 (BRD4 Protein Silencer)
PH-894, a member of the BET protein family, is a critical regulator of gen expression involved in cancer progression and metastasis. The primary challenge lies in precisely targeting BRD4, a task that has proven elusive for small molecule drug therapies that generate systemic toxicities, such as thrombocytopenia. PH-894 precisely silences only BRD4 offering the potential to reduce immune-related adverse events.
Learn more in Scientific Resources
Synergies with Antibodies
Synergies with Cell Therapies
PH-894 is an INTASYL compound that silences BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby effecting the immune system as well as the tumor.
Target(s) & Indication: BRD-4
Advanced Melanoma, Merkel Cell, HCC, TNBC
Scientific Resources
Investors
About us
Contact us
